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BACKGROUND AND PURPOSE: Effective management of patients with brain tumors depends on accurate detection and characteriza-
tion of lesions. This study aimed to demonstrate the noninferiority of gadoterate meglumine versus gadobutrol for overall visualization
and characterization of primary brain tumors.
MATERIALS AND METHODS: This multicenter, double-blind, randomized, controlled intraindividual, crossover, noninferiority study
included 279 patients. Both contrast agents (dose 0.1 mmol/kg of body weight) were assessed with 2 identical MRIs at a time interval of
2–14 days. The primary end point was overall lesion visualization and characterization, scored independently by 3 off-site readers on a
4-point scale, ranging from “poor” to “excellent.” Secondary end points were qualitative assessments (lesion border delineation, internal
morphology, degree of contrast enhancement, diagnostic confidence), quantitative measurements (signal intensity), and safety (adverse
events). All qualitative assessments were also performed on-site.
RESULTS: For all 3 readers, images of most patients (90%) were scored good or excellent for overall lesion visualization and character-
ization with either contrast agent; and the noninferiority of gadoterate meglumine versus gadobutrol was statistically demonstrated. No
significant differences were observed between the 2 contrast agents regarding qualitative end points despite quantitative mean lesion
percentage enhancement being higher with gadobutrol (P .001). Diagnostic confidence was high/excellent for all readers in81% of the
patients with both contrast agents. Similar percentages of patients with adverse events related to the contrast agents were observedwith
gadoterate meglumine (7.8%) and gadobutrol (7.3%), mainly injection site pain.
CONCLUSIONS: The noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary
brain tumors was demonstrated.
ABBREVIATIONS: AE adverse event; CNR contrast-to-noise ratio; GBCA gadolinium-based contrast agent; LS least-squares; r1 relaxivity
Gadolinium-based contrast agents (GBCAs) have led to im-provement in the diagnostic accuracy and sensitivity of MR
imaging. GBCAs can be classified into linear or macrocyclic
agents according to their chemical structure, with macrocyclic
GBCAs showing a higher kinetic stability.
Gadoterate meglumine is an ionic macrocyclic GBCA with a
measured T1 relaxivity (r1) range in plasma at 37°C of 3.4–3.8
Lmmol1 s1 at 1.5T and 3.3–3.7 Lmmol1 s1 at 3T.1
Gadobutrol is a nonionic macrocyclic GBCA with a higher r1
range of 4.9–5.5 L  mmol1  s1 at 1.5T and 4.7–5.3 L 
mmol1 s1 at 3T in plasma at 37°C.1
Gadobutrol is the onlyGBCA formulated at a concentration of
1 mmol/mL, while gadoterate meglumine is formulated at 0.5
mmol/mL, as are all other commercially available GBCAs ap-
proved for CNS imaging. Both are administered intravenously at
a dose of 0.1 mmol/kg of body weight; thus, gadobutrol is admin-
istered at half the volume of gadoterate meglumine. However,
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despite the small differences in relaxivity and in formulated drug
concentration, several neuroimaging studies have failed to con-
clusively demonstrate a clinical advantage for gadobutrol com-
pared with other GBCAs.2-4
The primary objective of this study was to determine whether
gadoterate meglumine is noninferior to gadobutrol for overall
visualization and characterization of primary brain tumors, using
an intraindividual crossover comparison design.
MATERIALS AND METHODS
Study Design
This study was a multicenter, double-blind, randomized, con-
trolled intraindividual, 2-sequence, 2-period, crossover noninfe-
riority study. Patients underwent 2 identical MR imaging exami-
nations, 1 with each contrast agent, gadoterate meglumine and
gadobutrol. The sequence of contrast agent administration (gad-
oteratemeglumine followed by gadobutrol or vice versa) was ran-
domly assigned to each patient with a 1:1 allocation ratio. This
study was conducted according to the principles in the Declara-
tion of Helsinki and the Good Clinical Practices guidelines of the
International Conference on Harmonization. In the United
States, the protocol was compliant with theHealth Insurance Por-
tability and Accountability Act. The study was approved by the
local ethics committee or institutional review board for human
subject research of each institution in which the study was per-
formed. Written informed consent was obtained from all partic-
ipating patients. The study was registered on https://clinicaltrials.
gov with identifier NCT02034708.
Patients
A total of 279 adult patients were enrolled in the study at 27
centers worldwide (Mexico, United States, South Korea, and Co-
lombia) between June 2014 and September 2015. Patients with
known or highly suspected primary brain (intracranial) tumors
detected by previous CT or MR imaging examination and who
were scheduled for contrast-enhanced MR imaging were in-
cluded. Patients were not included if they had a rapidly evolving
brain tumor that could change in appearance between the 2 MR
imaging examinations or if they were receiving treatment that
could result in a change of lesion appearance between the 2 MR
imaging examinations (eg, radiation therapy, an operation, or
chemotherapy). Additional noninclusion criteriawere the follow-
ing: patients who were pregnant or breastfeeding, had a contrain-
dication toMR imaging, had known severely impaired renal func-
tion (estimated glomerular filtration rate of 30 mL/min/1.73
m2), had known class III/IV congestive heart failure (New York
Heart Association Classification), had a known severe adverse drug
reaction or contraindication to GBCA, had received any contrast
agent within 48 hours before first study contrast agent injection or
were expected to receive any other contrast agent within 24 hours
following the last study contrast agent injection, or were included in
another clinical trial involving an investigational drugwithin 30 days
before the first contrast agent injection.
Contrast Agent Administration
Gadoterate meglumine (Dotarem; Guerbet, Aulnay-sous-Bois,
France) and gadobutrol (Gadovist, Bayer Schering Pharma, Ber-
lin, Germany; or Gadavist, Bayer HealthCare Pharmaceuticals,
Wayne, New Jersey) were each administered at a single dose of 0.1
mmol/kg of body weight (0.2 mL/kg for gadoterate meglumine,
0.1mL/kg for gadobutrol) by intravenous bolus injection at a rate
of 2mL/s with an automatic injector. Contrast agent injectionwas
immediately followed by a saline flush of 20–30 mL at the same
injection rate. To ensure that on-site evaluation of the contrast
agent was performed under blinded conditions, a third party per-
formed the injection. The patient was not aware of the identity of
the injected contrast agent. The 2MR imaging examinations were
performed with a minimum time interval of 48 hours to allow
contrast washout and prevent any effect of contrast agent carry-
over, and a maximum time interval of 14 days to minimize any
potential for lesion change and thus ensure comparability of the 2
examinations.
MR Imaging
MR imaging was performed on 1.5T systems in 15 centers and on
3T systems in 12 centers. Each MR imaging scanner was previ-
ously evaluated for qualification for the study by BioClinica
(Princeton, New Jersey). It was mandatory that the sameMR im-
aging scanner and same parameters be used for both examina-
tions in each patient. Imaging protocol included 3 unenhanced
sequences: axial T1-weighted (2D spin-echo or gradient recalled-
echo, or TSE with an echo-train length of3), axial T2-weighted
(2DTSE), and axial T2-weighted FLAIR (2D or 3D FLAIR); and 1
axial T1-weighted sequence post contrast-agent injection ac-
quired with imaging parameters identical to those of the precon-
trast axial T1 sequence (On-line Table 1). The postcontrast T1-
weighted imaging was initiated 5 1 minutes after the end of the
contrast agent injection.
Image Evaluation
All images were evaluated by 3 independent blinded off-site read-
ers. All were experienced (at least 12 years of experience with an
everyday practice in neuroradiology) and analyzed the images for
the following qualitative criteria: overall lesion visualization and
characterization (as the primary end point), lesion border delin-
eation, visualization of lesion internalmorphology, degree of con-
trast enhancement, and level of diagnostic confidence.
Overall visualization and characterization of the lesion (or
most representative lesion, ie, enhancing and/or largest if there
was1 lesion present) were assessed on a 4-point scale (0 poor,
inadequate; 1  fair, partial; 2  good, adequate; and 3 
excellent).
The level of diagnostic confidence was evaluated on a 5-point
scale according to the percentage of confidence (1 nil, 0%–4%;
2  poor, 5%–35%; 3  moderate, 36%–65%; 4  high, 66%–
95%; and 5 excellent, 96%–100%) for each patient based on the
most representative lesion. All available sequences (FLAIR, T2,
and T1 with and without contrast administration) were available
for readers to review and evaluate.
Border delineation and internal morphology were scored
on a 3-point scale (0 unevaluable; 1 seen, but imperfectly; and
2  seen completely/perfectly), as was the degree of contrast en-
hancement (0  nil; 1  mild enhancement; and 2  strong en-
hancement). These 3 criteria were assessed on up to 3 of the most
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representative lesions. For eachof these 3 criteria, a sumof scoreswas
calculatedat thepatient level as follows: scorelesion 1 ( scorelesion 2
scorelesion 3, if applicable) andwas recorded as a continuous variable.
Sums of scores were therefore related to the number of detected le-
sions. According to the results for sums of scores, images were clas-
sifiedas “gadoteratemegluminepreferred”when the sumof scoresof
the patient was superior with gadoterate meglumine; as “no prefer-
ence” when the sums of scores were equal with both contrast agents;
and as “gadobutrol preferred” when the sum of scores was superior
with gadobutrol.
Off-site readers also performed quantitative measures of sig-
nal intensity on up to 3 of the most representative lesions using
ROI markers to determine SNR, contrast-to-noise ratio (CNR),
and lesion percentage enhancement. ROIs were placed on unen-
hanced and enhanced T1 sequences.
The 3 off-site readerswere blinded to all patient data and to the
time point of the MR imaging examination (first or second), di-
agnostic results of the imaging procedures, findings of any other
readers (ie, investigators, on-site readers, other off-site readers),
and the contrast agent administered. Readers were trained on an
independent dataset of 15 MR imaging examinations to ensure a
harmonized understanding of the reading criteria and were qual-
ified after evaluation of inter- and intrareader variability on 15
new MR imaging examinations.
Study examinations were read in batches of approximately 30
examinations randomly distributed to each reader. Each reader
was permitted to analyze a maximum of 1 batch during any given
24-hour period. A “washout” period of at least 2 weeks between
examinations from the same patient was applied, and imageswere
distributed in random order between the 2 time points to mini-
mize recall bias.
In conditions more closely simulating the usual practice, an
on-site radiologist, blinded to the identity of the contrast agent,
also evaluated all images of patients included in his or her site with
the same qualitative criteria as described for the blinded readers.
These readings were used for patient management.
Safety
All adverse events (AEs) were recorded from the time of patient
enrollment in the study until 30 minutes after the last contrast
agent injection. The intensity of each adverse event was graded as
mild, moderate, or severe, and the causal relationship to the con-
trast agent was assessed by the investigator as being not related,
doubtfully related, or possibly related. All AEs were classified ac-
cording to the Medical Dictionary for Regulatory Activities, Ver-
sion 18.1 (https://www.meddra.org/) index terms.
Statistical Methods
Statistical analyses were performed by using SAS software (SAS
Institute, Cary, North Carolina), Version 9.2.
Primary and secondary criteria were presented on the per-
protocol set, including all randomized patients who had a valid
off-site assessment of the primary criterion without major proto-
col deviation. The primary criterion, the noninferiority of gadot-
erate meglumine–enhanced MR imaging compared with gad-
obutrol-enhanced MR imaging for overall lesion visualization
and characterization (dichotomized as good/excellent versus
poor/fair), was assessedwith a noninferioritymargin set at10%,
which was considered clinically acceptable. If one assumed that
approximately 85% of patients would have good or excellent le-
sion visualization and characterization (minimum score of 2) for
each contrast agent and each independent reader, approximately
235 patients undergoing the 2 MR imaging examinations were
needed to ensure that the difference between the 2 examinations
did not exceed the noninferiority margin. Assuming that 15% of
patients would withdraw from the study, 270 patients were
planned for randomization to achieve the study objective.
The noninferiority of gadoterate meglumine to gadobutrol
was declared if the lower limit of the 95% CI of the difference in
overall lesion visualization and characterization was above the
noninferiority margin for at least 2 of 3 off-site readers, using a
normal test of equality of paired proportions with a 1-sided 2.5%
significance level. To test the difference between the 2 contrast
agents, we performed amultiple logistic regressionmodel for cor-
related data. Secondary criteria were considered exploratory.
Comparison between the 2 contrast agents for continuous vari-
ables was performed with the differences of least-squares (LS)
mean from a mixed model for correlated data. The frequency of
the 3 classifications of sums of scores was compared using the
Wilcoxon signed rank test. The intra- and interreader agreement
for the evaluation of the overall lesion visualization and charac-
terization was assessed for each contrast agent and presented as
agreement proportion. Intrareader agreement was analyzed by
rereading 10% of all MR images, randomly determined. The 3




A total of 279 patients were enrolled in the study. Five were not
randomized due to deviation from the plan specified in the pro-
tocol (3 patients) or because theywithdrew consent (2 patients). A
total of 274 patients were randomized to either the gadoterate
meglumine/gadobutrol arm (140 patients) or the gadobutrol/
gadoterate meglumine arm (134 patients) to undergo 2 identical
MR imaging examinations. Six patients did not receive the first
contrast agent, leading to a total of 268 patients receiving at least 1
injection of contrast agent (safety set). Of these, 249 patients un-
derwent a second MR imaging with contrast agent injection and
completed the study with both contrast-enhanced MR imaging
examinations performed. Patient disposition is summarized in
Fig 1.
Among the 249 randomized patients who underwent bothMR
imaging examinations, 15were excluded from the per protocol set
because they presented with at least 1 major protocol deviation:
differences of MR imaging DICOM parameters at T1 sequences
between the 2 MR imaging examinations that could adversely
affect the comparability of lesion visualization and characteriza-
tion (n 3), technical injection failure in 1 of theMRIs (n 3), a
difference in injection rate of 1.5 mL/s between the 2 contrast
agent administrations (n 3), a difference of10% between the
2 actual doses administered to a single patient (n  2), patients
without detected tumoral lesions according to at least 2 off-site
readers at both examinations (n 3), and loss of the second MR
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imaging data (n  1). Therefore, the per-protocol set used for
analysis of evaluation criteria included 234 patients, 120 in the
gadoterate meglumine/gadobutrol arm and 114 in the gadobutrol/
gadoterate meglumine arm.
The 2 arms showed comparable demographic characteristics
(On-line Table 2). Patients ranged in age from 18 to 98 years, with
a mean of 53.6  15.1 years. There were more female than male
patients (64.2%versus 35.8%). Bodymass index ranged from17.4
to 51.2 kg/m2, with amean of 27.7 5.3 kg/m2. At the time of the
last brain imaging evaluation, the patients’ diagnoses were tumor
of the meninges (49.3%), glioma (14.9%), tumor not otherwise
specified (13.1%), pituitary adenoma (11.9%), nerve sheath tu-
mor (9.0%), tumor metastases (1.5%), and other (0.4%). Among
the 268 patients, 170 (63.4%) had a pre-
vious examination with GBCA adminis-
tration and only 1 of these patients
(0.4%) experienced a nonsevere adverse
reaction to the GBCA administered.
Primary Criterion: Overall Lesion
Visualization and Characterization
Figure 2 shows the results of the 3
blinded off-site readers for overall lesion
visualization and characterization. For
all readers, the overwhelming majority
of patients (90%) presentedwith good
or excellent overall lesion visualization
and characterization with either of the 2
contrast agents. Reader 3 scored overall
lesion visualization and characterization
as good or excellent for all patients with
gadoterate meglumine and for all pa-
tients except 1 with gadobutrol. There-
fore, a difference between these GBCAs
was not statistically evaluable for this
reader.
For the 2 other off-site readers, the es-
timated difference and 95% CI between
gadoteratemeglumine and gadobutrol (as
reference)was 2.3%(95%CI,1.3 to 5.9)
for reader 1 and2.5% (95%CI,6.5 to
1.4) for reader 2 with lower limits of 95%
CI above the noninferiority limit set at
10%. The noninferiority of gadoterate
meglumine compared with gadobutrol
was therefore demonstrated.
Figures 3 and 4 illustrate 2 case ex-
amples that demonstrate the identical
appearance in lesion visualization and
characterization observed for the 2 con-
trast agents.
Inter- and intrareader agreement
for the assessment of overall lesion vi-
sualization and characterization was
high on the basis of agreement propor-
tion, with interreader agreement rang-
ing from 91% to 96% and intrareader
agreement, from 96% to 100%.
The noninferiority of gadoterate meglumine compared
with gadobutrol was also demonstrated by on-site readers,
with 96% of patients presenting good or excellent overall
lesion visualization and characterization with both contrast
agents and an estimated difference between them of 0.6% (95%
CI, 1.8 to 3.1).
Qualitative Secondary Criteria
The 3 off-site readers scored border delineation, internal mor-
phology, and degree of contrast enhancement on up to 3 of the
most representative lesions; a sum of scores was calculated per
patient for each of these criteria (On-line Table 3). More than
87% of patients had only 1 lesion, 5%–10% had 2 lesions, and
FIG 1. Patient disposition with numbers of patients enrolled (n 279) and randomized (n 274)
to undergo 2 identical MR imaging examinations with gadoterate meglumine followed by gad-
obutrol (arm 1) or with gadobutrol followed by gadoterate meglumine (arm 2). A total of 268
patients received the first contrast agent injection, and 249 patients completed the study with
the 2 examinations performed.
FIG 2. Rate of patients with overall lesion visualization and characterization scored good/excel-
lent or poor/fair. The bar graph shows the rate of patients with overall lesion visualization and
characterization scored good/excellent or poor/fair according to each contrast agent and each
off-site reader (n 234 patients for all readers).
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4% had 3 lesions. Lesion border delineation showed no sig-
nificant differences between contrast agents for readers 1 and 2;
however, a minimal statistically significant difference (P .049)
was observed in favor of gadobutrol for reader 3. No statistically
significant differences between contrast agents were shown for
any of the 3 readers for visualization of lesion internal morphol-
ogy or for qualitative assessment of the degree of lesion contrast
enhancement.
The analysis by calculated preference of border delineation,
internal morphology, and degree of contrast enhancement be-
tween the 2 contrast agents showed no preference of the off-site
readers for most patients (68%–89%) (Fig 5). For the other pa-
tients (33% of patients), a slight calculated preference for gad-
obutrol was observed for readers 2 and 3, while a slight calculated
preference for gadoterate meglumine was seen for reader 1. These
differences were not statistically significant.
The mean level of diagnostic confidence was high or excellent
with both GBCAs in 81% of patients, according to all off-site
readers. No significant difference in diagnostic confidence was
observed between the 2 contrast agents.
Similar results were observed between on-site and off-site
readers regarding all the qualitative secondary criteria.
Quantitative Secondary Criteria: Signal-Intensity
Measurements
Results of signal-intensity measurements are presented in the
Table. LS mean SNR and CNR were higher with gadobutrol than
with gadoterate meglumine for all off-site readers, with an LS
mean difference ranging from10.3 to14.6 for SNR and from
7.4 to 23.6 for CNR. Statistically significant LS mean differ-
ences were observed for SNR for reader 1 (P .001) and for CNR
for readers 1 and 3 (P  .001 and P  .008). Significantly (P 
.001) higher values of lesion percentage enhancement were re-
ported with gadobutrol compared with gadoterate meglumine,
according to all readers, with LS mean differences ranging from
13.2 to15.7.
Adverse Events
A similar percentage of patients with postinjection AEs related
to contrast agent was observed with gadoterate meglumine
(7.8%, n  20 patients) and gadobutrol (7.3%, n  19 pa-
tients). The most frequent AEs related to gadoterate meglu-
mine were injection site pain (n  11) and paraesthesia at the
injection site (n 2) and at other sites (n 2), while the most
frequent AEs related to gadobutrol were injection site pain
(n  13), dizziness (n  2), and nausea (n  2). All these
postinjection AEs related to the contrast agents were mild or
moderate in intensity and resolved. Two patients had serious
AEs during the study (1 before and the other 8 days after con-
trast agent administration). For both patients, the serious AEs
were considered related to their primary brain tumor and not
related to the contrast agent.
DISCUSSION
The results from this study support the noninferiority of gadoter-
atemeglumine comparedwith gadobutrol, 2macrocyclic GBCAs,
for the diagnosis and evaluation of primary brain (intracranial)
tumors. Most patients (90%) presented with lesions that were
scored good/excellent for overall lesion visualization and charac-
terization by the readers with each contrast agent. No statisti-
cally significant differences were observed between the 2 GB-
CAs regarding the assessment of lesion border delineation (except
for 1 reader), lesion internal morphology, degree of contrast en-
hancement, or level of diagnostic confidence. The results for
blinded calculated reader preference based on the sumof scores at
the patient level for 3 of the secondary end points showed no
preference for either contrast agent in most cases (68%–89%).
When a preference was expressed for one or the other contrast
agent, the statistical analysis including the no preference sub-
group failed to show any statistically significant difference. De-
spite an LS mean difference in CNR, SNR, and lesion percentage
enhancement in favor of gadobutrol, which is considered clini-
callyminimal when relating it to the LSmean value of either of the
2 contrast agents, no discernible clinical effect was observed on
lesion visualization and characterization score. This suggests that
the level of contrast enhancement obtained with gadoterate me-
glumine provides comparable contrast visualization for evalua-
tion of primary brain tumors.
Several previous studies compared the efficacy of gadoterate
meglumine with that of other GBCAswith slightly different relax-
FIG 3. A 46-year-old woman with glioblastoma. T1 spin-echo images
(1.5T) after administration of 0.1 mmol/kg of gadoterate meglumine
(A) and gadobutrol (B) show an approximate 65-mm lesion. The time
between the 2 MR imaging examinations was 7 days. Lesion visualiza-
tion and characterization were scored as excellent by all 3 blinded
readers. The enhancing rim of the lesion is clearly seen on both
examinations.
FIG 4. A 74-year-old man with a high-grade glioma. T1 spin-echo im-
ages (1.5T) after administration of 0.1 mmol/kg of gadoterate meglu-
mine (A) and gadobutrol (B) show an approximate 30-mm mass. The
time between the 2 MR imaging examinations was 8 days. Lesion
visualization and characterization were scored as excellent by all 3
blinded readers. The mass is clearly seen on both examinations and
shows no difference in contrast enhancement.
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ivity values. Oudkerk et al5 compared gadoteratemeglumine with
gadopentetate dimeglumine, a linear ionic GBCA, in 1038 pa-
tients with CNS pathologies and showed comparable image qual-
ity with both contrast agents. However, one of the limitations of
the study is the lack of a crossover design. More recently, An-
zalone et al2 performed a single-blind, crossover comparison
study of gadobutrol versus gadoterate meglumine in 136 patients
with known brain lesions who underwent 2 identicalMR imaging
examinations, onewith each contrast agent.MR images were read
by 3 independent blinded readers in a matched-pairs comparison
in which both MR imaging series were displayed simultaneously.
Readers scored an overall preference for one or the other MR
imaging examination or “no preference” by using a 3-point scale:
1  gadobutrol better than gadoterate meglumine, 0  no pref-
erence, and 1  gadobutrol worse
than gadoterate meglumine. Secondary
end point evaluations included a prefer-
ence regarding the intensity of lesion en-
hancement, lesion delineation, and in-
ternal lesion structure. A statistically
significant overall preference for gad-
obutrol was noted by 2 of 3 readers.
However, no preference was expressed
by the off-site readers in the largest pro-
portion of cases (47% of patients). For
secondary assessment, a statistically sig-
nificant preference in favor of gad-
obutrol was noted by the 3 readers for
the level of enhancement but by only 1
reader for internal lesion structure and
by none of the readers for lesion delin-
eation. A major bias of the statistical
analysis of this studywas that it excluded
the “no preference” assessment group,
which was the largest group.6 Quantita-
tive assessment of the lesion-to-brain ra-
tio and lesion percentage enhancement
showed a statistically significant differ-
ence in favor of gadobutrol, which prob-
ably reflects the small difference in r1
between the 2 contrast agents. Most im-
portant, no clinical advantage for either
treatment group was demonstrated in
this study, and no differences were re-
ported in the number of lesions detected
with either contrast agent.
Gadobutrol was also compared with
other GBCAs in several studies. A com-
parison of the diagnostic performance of
gadobutrol and gadoteridol, another
macrocyclic agent with r1 relaxivity
comparable with that of gadoterate me-
glumine, was conducted by Katakami et
al4 in 175 patients with known or sus-
pected brain metastases. In this single-
blind, randomized, controlled intrain-
dividual crossover study, a single dose
and a double dose of gadobutrol, 1.0 mol/L (0.1 and 0.2 mmol/kg
of body weight, respectively), were demonstrated to be noninfe-
rior to a double dose of gadoteridol, 0.5 mol/L (0.2 mmol/kg of
body weight), at detecting brain metastases, with a comparable
mean number of lesions detected. Amajor limitation of this study
is that MR imaging examinations with gadoteridol were per-
formed only after the double dose; this feature did not allow a
head-to-head comparison of single doses of both contrast agents.
Maravilla et al3 reported a randomized double-blind crossover
study also comparing gadobutrol with gadoteridol, both at the
single dose of 0.1 mmol/kg. This study, including 229 patients,
showed the noninferiority of gadoteridol compared with gad-
obutrol for overall diagnostic lesion preference using a matched-
pairs comparison study design, as well as for secondary end points
FIG 5. Classification in preference subgroups for lesion border delineation (A), lesion internal
morphology (B), and degree of contrast enhancement (C). The bar graphs show the rate of
patients classified in preference subgroups for lesion border delineation (A), lesion internal
morphology (B), and degree of contrast enhancement (C), according to each off-site reader
(n  234 patients for all readers; n  231 patients for reader 1; n  233 patients for reader 2;









Reader 1 266.79 (5.00) 281.41 (5.02) 14.61 (22.77 to6.46) .001
Reader 2 157.21 (4.75) 167.46 (4.75) 10.26 (21.58 to 1.07) .076
Reader 3 192.94 (4.98) 203.35 (4.97) 10.41 (22.75 to 1.93) .098
CNR
Reader 1 117.22 (7.83) 140.84 (7.84) 23.62 (33.25 to13.99) .001
Reader 2 64.59 (4.19) 72.02 (4.19) 7.42 (14.87 to 0.03) .051
Reader 3 82.96 (5.16) 96.44 (5.15) 13.48 (23.43 to3.54) .008
Percentage enhancement
Reader 1 107.61 (3.93) 121.72 (3.93) 14.12 (18.38 to9.85) .001
Reader 2 93.90 (3.63) 107.12 (3.63) 13.22 (17.28 to9.16) .001
Reader 3 98.82 (3.77) 114.47 (3.76) 15.66 (20.52 to10.79) .001
Note:—SE indicates standard error.
a LS means are the means controlled for covariates of the model.
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of lesion border delineation, internal morphology, lesion extent,
and lesion contrast enhancement. In addition, a blinded reader
assessment of the diagnostic characterization of lesions as benign
or malignant showed no statistically significant difference be-
tween the 2 contrast agents for 2 of 3 readers.
Another limitation of the study is that nearly 60% of patients
presented with extra-axial tumors, meningiomas, or nerve sheath
tumors, which should readily enhance regardless of agent and
magnetic field strength.
Therefore, the results of the present study are consistent with
previous reports showing no difference in clinical benefit between
the 2 contrast agents, with slightly different relaxivity values. In
our study, a rigorous, double-blind, controlled intraindividual,
2-sequence, 2-period crossover design was chosen to compare
gadoterate meglumine with gadobutrol. The study design differs
slightly from some other crossover comparison studies because
blinded readers used a 4-point scale graded frompoor to excellent
to rank the primary end point of overall lesion visualization and
characterization for each individualMR imaging examination in-
dependently and in a randomized order. The present methodol-
ogy aimed to simulate the clinical daily practice inwhich contrast-
enhanced MR imaging must allow good visualization and
characterization of lesions, which ensures appropriate medical
care of patients. The very high interreader agreement proportion,
ranging from 91% to 96% for the assessment of overall lesion
visualization and characterization, and the consistency observed
between off-site and on-site readers demonstrate the robustness
of our results.
Unlike inMaravilla et al,3 the accuracy for lesion characteriza-
tion with histopathologic confirmation was not appraised in our
study. The level of diagnostic confidence and radiologic diagnosis
was assessed, but histopathologic confirmation ensuring the va-
lidity of the diagnosis was lacking. Another limitation of this study
was that we did not evaluate the impact of contrast-enhancedMR
imaging on patientmedicalmanagement. A follow-up study eval-
uating patient management after contrast-enhancedMR imaging
with gadoterate meglumine or gadobutrol would be needed to
confirm the clinical significance of these results.
The use of any contrast agent must be based on clinical need
and diagnostic indications. Once the diagnostic indications are
met, the choice of which contrast agent to use is based on balanc-
ing the benefit to be gained (eg, adequate visualization) versus the
risk of use. Gadoterate meglumine has been used for28 years as
a safe and efficient MR imaging GBCA. There have been 60
million doses administered worldwide, with an excellent safety
profile for immediate adverse drug reactions and a low incidence
of serious AEs, comparable with other extracellular GBCAs.7 This
study confirms the low incidence of immediate AEs reported with
gadoterate meglumine and with gadobutrol as demonstrated in
multiple previous studies.7,8 All AEs were mild or moderate in
degree and resolved; no serious AEs related to either contrast
agent were reported during the study.
Thus, the present results also support the comparable safety
profile of gadoterate meglumine versus gadobutrol.
The discovery of the association of GBCAs with nephrogenic
systemic fibrosis in patients with severe renal failure9,10 and,more
recently, with brain gadolinium deposition11-13 in patients with
normal renal function raises important safety concerns in the field
of contrast-enhanced MR imaging, which influence radiologic
practice. Most important, no or very few cases of nephrogenic
systemic fibrosis have been reported after highly stable macrocy-
clic GBCA administration (no cases of nephrogenic systemic fi-
brosis associatedwith unconfounded single-agent administration
of gadoteratemeglumine), and brain T1 hyperintensities have not
been observed after administration of any of the macrocyclic
GBCAs.12-16 The emergence of these safety issues related to the
use of GBCAs should encourage the choice of the most stable
macrocyclic contrast agents in clinical practice.
CONCLUSIONS
This multicenter, randomized, double-blind, controlled intrain-
dividual crossover study demonstrates the noninferiority of gad-
oteratemeglumine versus gadobutrol for overall visualization and
characterization of primary brain tumors in 234 patients, sup-
ported by no preference of the readers for either contrast agent, in
most cases, regarding border delineation, internal morphology,
and the qualitative degree of contrast enhancement. Despite the
difference in relaxivity between these 2 GBCAs, no measurable
difference in clinical benefit was observed in our study. A similar
safety profile was also demonstrated for both contrast agents.
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